We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study.
- Authors
Zhang, Y. L.; Zhou, C.; Li, X. F.; Yang, M. N.; Tao, L.; Zheng, X. Y.; Jia, Y. S.
- Abstract
Summary: Aims: The purpose of this study was to examine the effectiveness of beinaglutide on body weight, glycated haemoglobin (HbA1c), blood pressure and lipid profiles in patients with type 2 diabetes mellitus (T2DM) in a real‐world setting in China. Materials and methods: This was a multicentre, observational, retrospective, open‐label study conducted in China. Data were collected from T2DM patients who started treatment with beinaglutide between 2017 and 2018. Results: A total of 314 patients were included in the study. After 3 months of treatment with beinaglutide, there were significant reductions in body weight (−10.05 kg [95% confidence interval −9.29 to −10.80]), HbA1c (−2.87% [−2.62 to −3.11]), 2‐h postprandial plasma glucose (−5.46 mmol L−1 [−4.96 to −5.95]) and fasting plasma glucose (−3.04 mmol L−1 [−2.78 to −3.31]) (all p < 0.0001). In addition, 84.96% and 72.18% of the patients achieved weight loss of ≥5% and ≥10%, respectively. Subgroup analyses showed that weight loss was significantly greater in patients with ≥28 kg m−2 of baseline body mass index and 0.60 mg of beinaglutide doses (p = 0.007 and p < 0.0001, respectively). HbA1c reductions were significantly greater in patients with ≥9.0% baseline HbA1c and in those administered 0.40–0.48 mg of beinaglutide doses (all p < 0.0001). Weight loss at 3 months was positively correlated with baseline BMI and the dose of beinaglutide. Positive determinants for HbA1c reduction after 3 months were baseline HbA1c and the dose of beinaglutide. Conclusions: These observational results confirmed the benefits of beinaglutide in weight loss and glycaemic control and support the use of beinaglutide as an effective treatment for T2DM.
- Subjects
CHINA; TYPE 2 diabetes; WEIGHT loss; BODY mass index; BODY weight
- Publication
Obesity Science & Practice, 2019, Vol 5, Issue 4, p366
- ISSN
1120-1520
- Publication type
Article
- DOI
10.1002/osp4.342